Abiopharma

Entrada Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference

EyePoint to Present at the 44th Annual J.P. Morgan Healthcare Conference

Landmark Study Shows Combination of Castle Biosciences DecisionDx®-UM and PRAME Outperforms Gene Mutation Analysis in Predicting Survival Outcomes in Uveal Melanoma

Tango Therapeutics to Participate in 44th Annual J.P. Morgan Healthcare Conference

Lifecore Biomedical Signs CDMO Master Services Agreement with New Large Multinational Pharmaceutical Customer

Nuvectis Pharma Announces the Initiation of the Phase 1b Study of NXP900 in Combination with Osimertinib in Patients with NSCLC

Viatris to Present at the 44th Annual J.P. Morgan Healthcare Conference

Protalix Biotherapeutics and Secarna Pharmaceuticals Enter into Collaboration and Option Agreement

KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) Significantly Improved Event-Free Survival, Overall Survival and Pathologic Complete Response Rates for Cisplatin-Eligible Patients with MIBC When Given Before and After Surgery

Veru Reports Fiscal Year 2025 Financial Results and Clinical Program Progress